Orchard Therapeutics

101 Seaport Boulevard, 7th Floor
Boston
MA
02210
United States

About Orchard Therapeutics

Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.

Orchard’s portfolio of ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis^®, the first ex vivo autologous gene therapy approved by the EMA in 2016, three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline.

The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London and Boston.

117 articles with Orchard Therapeutics

Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey

1/19/2021

Orchard Therapeutics, a global gene therapy leader, announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional specialty pharmaceutical companies with extensive experience in rare genetic disease.
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)

1/14/2021

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200,
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications

1/11/2021

Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

1/5/2021

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday January 13, 2021 at 9:10 AM ET.
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)Preliminary results from first patient treated with OTL-201

12/8/2020

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy being studied for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A). The data were presented as part of an oral pres
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

11/24/2020

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020. The fireside chat is available for on-demand viewing under "Events" in the Investors &
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)

11/19/2020

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy (MLD). The company also has applied for Regenerative Medicine Advanced Therapy (RMAT) des
First Combined Test for COVID-19, Influenza A and Influenza B Now Available in Metro Detroit

11/17/2020

Orchard Laboratories, headquartered in West Bloomfield, Mich. (7901 Orchard Lake Road, Suite 100), is the first private laboratory in metro Detroit to operate the new, TaqPath Multiplex Kit to test for SARS-CoV-2, Influenza A and Influenza B.
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET

11/12/2020

First look at preclinical data infrontotemporal dementia with progranulin mutations (GRN-FTD)and new amyotrophic lateral sclerosis (ALS) program
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit

11/9/2020

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020 at 11:15 AM ET.
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting

11/5/2020

Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results

11/3/2020

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reviewed recent business accomplishments and reported financial results for the quarter ended September 30, 2020.
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020

11/2/2020

Orchard Therapeutics, a global gene therapy leader, announced that the company will webcast a virtual R&D event ‘New Horizons in Gene Therapy’ on Friday, November 13, 2020 from 9:00 a.m. to 11:00 a.m. ET.
BioSpace Movers & Shakers, Oct. 23

10/23/2020

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors

10/22/2020

Orchard Therapeutics, a global gene therapy leader, announced that the company’s chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicine’s 2021 board of directors.
BioSpace Global Roundup, Oct. 22

10/22/2020

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

10/16/2020

First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants
BioSpace Global Roundup, Oct. 1

10/1/2020

Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I

9/28/2020

Orchard Therapeutics, a global gene therapy leader, announced that the European Medicines Agency has granted Priority Medicines designation to OTL-203, an investigational ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.
Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences - Sep 09, 2020

9/9/2020

Orchard Therapeutics, a global gene therapy leader, announced that the company is scheduled to present at the following virtual investor conferences in September

First
1
2
3
4
5
Next
Last